Bay area biotech StemCells to wind down.

Bay area biotech StemCells to wind down.

They were working on a spinal chord treatment but their clinical trials have failed. Bay area biotech “StemCells” (I was surprised they didn’t “invest” in the .com version of their name) which was publicly traded  will wind down operations. They are hoping to see what can be salvaged for investors and skirt a 100% loss. At their peak: $74 million market cap. Now, not so much. ($6 million) They also raised 32 million in two…

Read More

Violin Memory posts 20M+ quarterly loss (again…and again…)

Violin Memory posts 20M+ quarterly loss (again…and again…)

Publicly traded memory maker Violin Memory (VMEM) has posted another quarterly loss in excess of $20M (this is the third or fourth in a row), begging TheRegister to wonder aloud “can they avoid a trainwreck?” Keep in mind, the market cap of the entire company is $36M, which means they are successively putting up quarterly losses worth roughly 2/3 the company’s market cap. This, after 7 funding rounds totalling $187M, their Series D valued them at…

Read More

Hub Nation & The Scandal of Money

Hub Nation & The Scandal of Money

I just finished reading Dan Lyon’s “Disrupted”. I devoured it in a little over 2 days and took frequent breaks to email various friends and colleagues (many of them tech CEOs of non-unicorns, go figure) that they had to read it. The story of Lyon’s tumultuous ride at Hubspot, a tech unicorn which has never shown a profit, and will probably never show a profit didn’t tell me anything I didn’t already know. It didn’t…

Read More